Advertisement

Advertisement

2017 City of Hope Hematologic Malignancies Symposium

By Chase Doyle / May 10, 2017 / 2017 City of Hope Hematologic Malignancies Symposium

Blinatumomab ‘Takes a BiTE’ Out of Acute Lymphoblastic Leukemia

An investigational immunotherapy is improving outcomes in difficult-to-treat acute lymphoblastic leukemia (ALL) and showing promise in other cancers, as well. Blinatumomab (Blincyto), the first U.S. F...

Multiple Myeloma

By Chase Doyle / May 10, 2017 / 2017 City of Hope Hematologic Malignancies Symposium

Immune System Is Shaping the Future of Multiple Myeloma Treatment

From immunomodulatory agents and proteasome inhibitors to steroids, alkylators, and antibodies, recent years have witnessed an explosion of drug approvals for multiple myeloma. The challenge now, sai...

Advertisement

Advertisement

Nov

22

Today In Oncology

Perioperative Toripalimab in Locoregionally Advanced Nasopharyngeal Carcinoma

Impact of ASH Minority Recruitment Initiative on Retaining, Engaging Underrepresented Hematologists

Addition of Hyperthermic Intraperitoneal Chemotherapy to Surgery for Recurrent Ovarian Cancer

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

Advertisement

© 2024 HSP News Service, L.L.C.